EFFICACY AND SAFETY OF ADALIMUMAB AFTER INFLIXIMAB FAILURE IN PEDIATRIC ULCERATIVE COLITIS: A REAL-LIFE EXPERIENCE FROM THE SIGENP-IBD REGISTRY



This item was part of UEG Week 2017